EBMT 2021 | Challenges of CAR-T bridging to allo-SCT
Livio Pagano • 8 Mar 2021
Livio Pagano, MD, Catholic University of Sacred Heart, Rome, Italy, discusses challenges associated with using chimeric antigen receptor T-cell (CAR-T) therapy as a bridging therapy to allogeneic stem cell transplantation (allo-SCT), outlining the increased risk of fungal infection. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
Disclosures
Prof. Livio Pagano, MD, discloses connections to Jazz Pharmaceuticals, Janssen, Novartis, Gilead, Menarini, Cidara Therapeutics, Stemline, Pfizer and MSD.
